Date & time
Medicines for Malaria Venture (MMV) is a global public-private and civil society collaboration that mobilises and shares knowledge and expertise, technology and financial resources to address the global health challenge posed by malaria.
MMV’s partners - including 28 pharmaceutical companies, 13 biotechs, 56 universities, 38 research institutes, 72 clinical sites and 50 government agencies - have developed the largest ever global pipeline of new antimalarial medicines. MMV and partners are now working on the development of an effective single dose cure that will tackle drug resistance and facilitate malaria eradication and elimination.
In this public lecture, Medicines for Malaria Venture CEO David Reddy discussed the impact, progress and opportunities that are driving global best practice for malaria drug development, and explained how product development partnerships are tackling global health challenges like malaria.
Dr David Reddy has been CEO of Medicines for Malaria Venture since January 2011. Under his leadership, this not-for-profit research foundation has brought forward five new antimalarial drugs, broadened its malaria-drug pipeline to include nine novel drugs in clinical development.
Prior to joining MMV, David was a Vice President in the Global Product Strategy Unit at F. Hoffman-La Roche Ltd in Basel, Switzerland, where he served as Pandemic Taskforce Leader. Prior to that he was the Global Franchise Leader for HIV/AIDS at Roche, where he oversaw the successful development and introduction of enfuvirtide, the first HIV fusion inhibitor.
This public lecture was presented by the Development Policy Centre at Crawford School of Public Policy, The Australian National University.